Our discovery platform provides unprecedented insight on activity, target and mechanism for new molecules. We then bring forward the finest of these novel molecules that address the most urgent needs of patients.
The lead asset class of glycomacrolides are potent and selective inhibitors of the F1 subunit of ATP synthase/hydrolase with optimal pharmacology, and a wide therapeutic index in patient-derived tumor models. EB6103 and EB9092 are novel bioengineered compounds undergoing IND enabling studies. Undisclosed leads in discovery and optimization continue to make their way toward the clinic.
Preclinical data provides a strong rationale for initial lead asset development in leukemia and several solid tumors targeting an unmet medical need and providing a pathway for accelerated approval.
First-in-class novel mechanism of action
Scaling advantages from growing compounds in organisms
Multiple potential indications
Join us as we explore the depths of discovery.
